FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Drought of approvals gets worse for developers

The long dry spell for new drug approvals has actually worsened a bit. In Vivo notes that the FDA approved six new molecular entities in the first half of the year, down one from the dreadful pace set in 2007. Last year only 16 NMEs made it through, the worst record in a generation at a time that pharma companies have been desperate to add new products to their lineup.

But don't panic yet. In Vivo also notes that there are at east 30 NMEs up for approval at the FDA with a PDUFA date falling prior to New Year's Day. And even though the FDA is increasingly likely to blow off its deadlines, there's still a good chance that 2008 will turn out better than 2007. Let the office pools begin.

- check out the report from In Vivo

Related Articles:
FDA picking up the pace on '08 approvals
2007 FDA approvals
2008 NME approvals no better than last year?
Dry spell or parched desert for NME approvals?
'07's drug approval record raises worries
New drug approval lags in 2007


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about FDA approval   Drug approvals   NME approvals   FDA update